Table 1. Patient characteristics (n = 95).
| Characteristic | Data | |
|---|---|---|
| Age (y)—mean ± standard deviation | 60.8 ± 11.6 | |
| Male | 61.1 ± 11.9 | |
| Female | 60.2 ± 11.2 | |
| Male | 59 (62.1%) | |
| Clinical staging according to CT findings | ||
| Ia | 2 (2.1%) | |
| II | 14 (14.7%) | |
| III | 79 (83.2%) | |
| IV | 0 (0.0%) | |
| CT machine | ||
| 16 channel | 15 (15.8%) | |
| 64 channel | 80 (84.2%) | |
| CCRT regimen | ||
| XELOX | 45 (47.4%) | |
| FOLFOX | 46 (48.4%) | |
| Cetuximab/Irino/Xeloda | 4 (4.2%) | |
| Pathologic response | ||
| Grade 1 | 17 (17.9%) | |
| Grade 2 | 46 (48.4%) | |
| Grade 3 | 18 (19.0%) | |
| Grade 4 | 14 (14.7%) | |
| Tumor recurrence | 18 (18.9%) | |
a Two patients were considered to have locally advanced cancer, according to the MRI findings.